Sator Therapeutics

We are an oncology company that is focused on the development of oncolytic viruses that are able to selectively kill cancer cells and secondarily illicit a natural immune response. SATOR Therapeutics has developed a library of 30 oncolytic viruses which have demonstrated a differential response across multiple cancers where several viruses have shown efficacy across multiple indications. The viruses are non-engineered, non-pathogenic and can be administered systemically via IV. These viruses were collected over decades of research and by combining them can overcome many of the challenges associated with a single oncolytic virus and neutralizing antibodies while avoiding the safety problems associated with engineered viruses. Additionally, SATOR has developed a diagnostic approach for predicting efficacy as well as a next-generation delivery approach using dendritic cells.